336 related articles for article (PubMed ID: 28536321)
1. [Disruption of gut immune system caused by damage of intestinal stem cells and their niche in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.].
Hayase E; Teshima T
Clin Calcium; 2017; 27(6):829-833. PubMed ID: 28536321
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
Ara T; Hashimoto D
Front Immunol; 2021; 12():713631. PubMed ID: 34512636
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. [Key players in intestinal GVHD].
Hashimoto D; Teshima T
Rinsho Ketsueki; 2015 Jul; 56(7):807-14. PubMed ID: 26251143
[TBL] [Abstract][Full Text] [Related]
5. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
6. Intestinal microbiota-related effects on graft-versus-host disease.
Shono Y; Docampo MD; Peled JU; Perobelli SM; Jenq RR
Int J Hematol; 2015 May; 101(5):428-37. PubMed ID: 25812838
[TBL] [Abstract][Full Text] [Related]
7. Acute Graft-versus-Host Disease: Novel Biological Insights.
Teshima T; Reddy P; Zeiser R
Biol Blood Marrow Transplant; 2016 Jan; 22(1):11-6. PubMed ID: 26453971
[TBL] [Abstract][Full Text] [Related]
8. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
Shono Y
Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
[TBL] [Abstract][Full Text] [Related]
9. Decreased secretion of Paneth cell α-defensins in graft-versus-host disease.
Eriguchi Y; Nakamura K; Hashimoto D; Shimoda S; Shimono N; Akashi K; Ayabe T; Teshima T
Transpl Infect Dis; 2015 Oct; 17(5):702-6. PubMed ID: 26198302
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
Norona J; Apostolova P; Schmidt D; Ihlemann R; Reischmann N; Taylor G; Köhler N; de Heer J; Heeg S; Andrieux G; Siranosian BA; Schmitt-Graeff A; Pfeifer D; Catalano A; Frew IJ; Proietti M; Grimbacher B; Bulashevska A; Bhatt AS; Brummer T; Clauditz T; Zabelina T; Kroeger N; Blazar BR; Boerries M; Ayuk F; Zeiser R
Blood; 2020 Sep; 136(12):1442-1455. PubMed ID: 32542357
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
12. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. TNFAIP8 Deficiency Exacerbates Acute Graft Versus Host Disease in a Murine Model of Allogeneic Hematopoietic Cell Transplantation.
Kumari R; Palaniyandi S; Strattan E; Huang T; Kohler K; Jabbour N; Dalland J; Du J; Kesler MV; Chen YH; Hildebrandt GC
Transplantation; 2020 Mar; 104(3):500-510. PubMed ID: 31634333
[TBL] [Abstract][Full Text] [Related]
15. The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
Hidaka D; Hayase E; Shiratori S; Hasegawa Y; Ishio T; Tateno T; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Endo T; Hashimoto D; Teshima T
Clin Transplant; 2018 Sep; 32(9):e13361. PubMed ID: 30054935
[TBL] [Abstract][Full Text] [Related]
16. The Gut Microbiota and Hematopoietic Stem Cell Transplantation: Challenges and Potentials.
Noor F; Kaysen A; Wilmes P; Schneider JG
J Innate Immun; 2019; 11(5):405-415. PubMed ID: 30286447
[TBL] [Abstract][Full Text] [Related]
17. Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice.
Buchele V; Büttner-Herold M; Vogler T; Neurath MF; Hildner K
J Vis Exp; 2019 Feb; (144):. PubMed ID: 30799849
[TBL] [Abstract][Full Text] [Related]
18. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
19. Targeting the IL17 pathway for the prevention of graft-versus-host disease.
van der Waart AB; van der Velden WJ; Blijlevens NM; Dolstra H
Biol Blood Marrow Transplant; 2014 Jun; 20(6):752-9. PubMed ID: 24565991
[TBL] [Abstract][Full Text] [Related]
20. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.
Köhler N; Zeiser R
Front Immunol; 2018; 9():3179. PubMed ID: 30705680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
